A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
Clinical trial NCT04014335 · COMPLETED
Trial details
- NCT number
- NCT04014335
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-04
- Primary completion
- 2024-02-08
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.